H.C. Wainwright cuts Palvella Therapeutics' target price to $246 from $270
PVLA•H.C. Wainwright cut its target price for Palvella Therapeutics to $246 from $270.
Related News
The Hartford Insurance Group coverage initiated with hold rating and $137 price target
HIG•
Digital Currency X Technology enters strategic investment and exclusive commercialization agreement with Whales AI
DCX•
StoneX raises Cantor Equity Partners II target price to $18 from $12
SECZ•
UFP Industries target price cut to $104 from $108
UFPI•
Bristol Myers cancer therapy meets main goal in late-stage study
BMY•